Interpace Diagnostics Group (IDXG) AI Stock Analysis

• Market Cap: $6.20M
• Dividend Yield: N/A
• Average Volume (3M): 11.83K
• Price to Earnings (P/E): 5.2
• Beta (1Y): 1.19
• Revenue Growth: -6.64%
• EPS Growth: -29.74%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.03
• Shares Outstanding: 4,428,539
• 10 Day Avg. Volume: 13,958
• 30 Day Avg. Volume: 11,832
• PEG Ratio: <0.01
• Price to Book (P/B): -5.34
• Price to Sales (P/S): 0.25
• P/FCF Ratio: 3.14
• Enterprise Value/Market Cap: 4.16
• Enterprise Value/Revenue: 0.62
• Enterprise Value/Gross Profit: 0.95
• Enterprise Value/Ebitda: 4.25
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: $1.50 ▲(59.57% Upside)

The stock score is primarily driven by strong financial performance and undervaluation, despite technical indicators suggesting overbought conditions. The company's strategic debt repayment further supports its growth potential, although negative equity remains a concern.

Positive Factors

Cash Flow Improvement

The strong recovery in cash generation capabilities enhances liquidity and financial stability, supporting long-term operational needs.

Debt Reduction

Reducing debt levels enhances financial flexibility and reduces interest burden, supporting sustainable growth and stability.

Profit Margin Improvement

Improved profit margins reflect efficient cost management and robust operating performance, enhancing long-term profitability.

Negative Factors

Negative Equity

Negative equity poses risks to financial stability, limiting the company's ability to absorb losses and invest in growth opportunities.

Revenue Growth Decline

Despite recent growth, the overall revenue growth trend is negative, which could impact future earnings and market position.

Solvency Concerns

Solvency concerns due to negative equity and financial challenges may hinder long-term operational and strategic flexibility.

Interpace Diagnostics Group Business Overview & Revenue Model

Company Description

Interpace Diagnostics Group (IDXG) is a biotechnology company specializing in developing and commercializing molecular diagnostic tests for cancer and other diseases. The company operates primarily in the healthcare sector, focusing on providing innovative diagnostic solutions that aid in the early detection and management of cancer, particularly in the gastrointestinal field. IDXG's core products include a portfolio of molecular tests designed to improve diagnostic accuracy and inform treatment decisions for patients, thereby enhancing patient outcomes.

How the Company Makes Money

IDXG generates revenue primarily through the sale of its diagnostic tests, which are utilized by healthcare providers to assess and diagnose cancer. The company's revenue model includes direct sales to hospitals and laboratories, as well as partnerships with other healthcare organizations and pharmaceutical companies that may utilize IDXG's technologies in their services. Additionally, IDXG may earn revenue through reimbursement from insurance providers for the diagnostic tests performed, which is a significant revenue stream. The company also engages in collaborations and licensing agreements that can enhance its market presence and generate additional income, contributing to its overall earnings.

Interpace Diagnostics Group Financial Statement Overview

Summary

Interpace Diagnostics Group shows strong revenue growth and improved profitability with a net profit margin of 14.3% and revenue growth of 16.7%. However, the negative equity of -$2.2 million poses a significant risk, despite improvements in debt reduction and cash flow.

Income Statement

Interpace Diagnostics Group has shown a significant improvement in its income statement metrics over the recent years. The gross profit margin for 2024 stands at 63.8%, reflecting efficient cost management. The net profit margin improved to 14.3%, indicating strong profitability. Revenue growth rate from 2023 to 2024 was 16.7%, showing solid growth momentum. The EBIT margin of 17.3% and EBITDA margin of 17.8% for 2024 suggest robust operating performance. Overall, the income statement reveals a positive growth trajectory and improved profitability.

Balance Sheet

The balance sheet shows ongoing financial challenges, with a negative stockholders' equity of -$2.2 million in 2024, indicating potential solvency issues. However, the company has reduced its debt levels significantly over time, with a debt-to-equity ratio improvement as total debt decreased to $1.18 million. Return on equity is not meaningful due to negative equity. The equity ratio remains negative, further emphasizing balance sheet weaknesses. Improvements in reducing debt and liabilities are positive steps, but negative equity poses risks.

Cash Flow

Cash flow analysis highlights a strong recovery in cash generation capabilities. The operating cash flow in 2024 was $4.65 million, significantly higher than in previous years. Free cash flow improved to $3.77 million, indicating better cash management. The free cash flow growth rate from 2023 to 2024 is 13.6%, showcasing effective capital allocation. The operating cash flow to net income ratio of 0.69 indicates efficient cash conversion. Overall, the cash flow statement reflects positive trends in liquidity and cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.82M	46.93M	40.21M	31.84M	41.31M	32.40M
Gross Profit	27.00M	29.93M	23.90M	18.23M	17.95M	10.72M
EBITDA	6.06M	8.36M	3.84M	-2.27M	-1.33M	-20.10M
Net Income	4.81M	6.70M	802.00K	-5.87M	-14.75M	-26.20M
Balance Sheet
Total Assets	12.04M	14.79M	13.02M	15.98M	38.43M	45.68M
Cash, Cash Equivalents and Short-Term Investments	1.42M	1.46M	3.50M	4.83M	3.31M	2.77M
Total Debt	864.00K	5.86M	11.19M	16.09M	13.72M	4.74M
Total Liabilities	12.33M	17.01M	28.16M	79.05M	80.84M	74.76M
Stockholders Equity	-298.00K	-2.22M	-15.14M	-63.07M	-42.42M	-29.08M
Cash Flow
Free Cash Flow	2.61M	3.77M	3.32M	-8.01M	-9.07M	-16.15M
Operating Cash Flow	2.94M	4.65M	3.79M	-7.69M	-8.72M	-14.58M
Investing Cash Flow	-330.00K	-876.00K	-87.00K	6.21M	-315.00K	-1.57M
Financing Cash Flow	-4.22M	-5.81M	-5.03M	3.00M	8.98M	16.61M

Interpace Diagnostics Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.94
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXG, the sentiment is Positive. The current price of 0.94 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.01, and above the 200-day MA of 0.93, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 64.49 is Neutral, neither overbought nor oversold. The STOCH value of 72.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDXG.

Interpace Diagnostics Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDXG	62 Neutral	$6.20M	5.20	―	―	-6.64%	-29.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INBS	46 Neutral	$5.34M	―	-223.45%	―	3.26%	65.96%
BIAF	46 Neutral	$9.40M	-0.10	-245.18%	―	-27.66%	13.18%
MYNZ	41 Neutral	$7.52M	―	―	―	―	―
NDRA	34 Underperform	$5.82M	-0.01	-236.34%	―	―	98.86%
CHEK	26 Underperform	$9.13M	―	―	―	―	―

Interpace Diagnostics Group Corporate Events

Interpace Biosciences Repays Loan Early for Growth

On December 3, 2025, Interpace Biosciences announced the early repayment of its term loan facility with BroadOak Capital Partners, ahead of its maturity date. This move eliminates interest expenses and enhances operational flexibility, allowing the company to focus on commercial growth and strengthen its balance sheet, as it continues to deliver record testing volumes and revenue for its thyroid tests.